AU2004222435B2 - Angiotensin-converting enzyme inhibitory peptides - Google Patents
Angiotensin-converting enzyme inhibitory peptides Download PDFInfo
- Publication number
- AU2004222435B2 AU2004222435B2 AU2004222435A AU2004222435A AU2004222435B2 AU 2004222435 B2 AU2004222435 B2 AU 2004222435B2 AU 2004222435 A AU2004222435 A AU 2004222435A AU 2004222435 A AU2004222435 A AU 2004222435A AU 2004222435 B2 AU2004222435 B2 AU 2004222435B2
- Authority
- AU
- Australia
- Prior art keywords
- val
- tyr
- peptide
- composition according
- tripeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101710178392 Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 78
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 59
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 59
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 59
- 230000002401 inhibitory effect Effects 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 32
- MSFITIBEMPWCBD-ULQDDVLXSA-N Leu-Val-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MSFITIBEMPWCBD-ULQDDVLXSA-N 0.000 claims description 28
- 206010020772 Hypertension Diseases 0.000 claims description 11
- 230000036772 blood pressure Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 235000013361 beverage Nutrition 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 108090001109 Thermolysin Proteins 0.000 description 16
- 230000029087 digestion Effects 0.000 description 16
- 235000013305 food Nutrition 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 244000075850 Avena orientalis Species 0.000 description 12
- 235000007319 Avena orientalis Nutrition 0.000 description 12
- 240000007594 Oryza sativa Species 0.000 description 12
- 235000007164 Oryza sativa Nutrition 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 235000007558 Avena sp Nutrition 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 244000000231 Sesamum indicum Species 0.000 description 11
- 235000003434 Sesamum indicum Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 235000009566 rice Nutrition 0.000 description 11
- 230000001077 hypotensive effect Effects 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 7
- BZWUSZGQOILYEU-STECZYCISA-N Val-Ile-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BZWUSZGQOILYEU-STECZYCISA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000012264 purified product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 101800004538 Bradykinin Proteins 0.000 description 4
- 102400000967 Bradykinin Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- 102400000345 Angiotensin-2 Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 240000006677 Vicia faba Species 0.000 description 3
- 235000010749 Vicia faba Nutrition 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002952 polymeric resin Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098345 Triticum durum Species 0.000 description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
- QSXSHZIRKTUXNG-STECZYCISA-N Ile-Val-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QSXSHZIRKTUXNG-STECZYCISA-N 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MDSUKZSLOATHMH-UHFFFAOYSA-N N-L-leucyl-L-valine Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000893841 Schlechterella abyssinica Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 244000191914 Triticum persicum Species 0.000 description 1
- 240000002805 Triticum turgidum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009236034A AU2009236034B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
| AU2009236033A AU2009236033B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003074488 | 2003-03-18 | ||
| JP2003-074488 | 2003-03-18 | ||
| PCT/JP2004/003588 WO2004082709A1 (en) | 2003-03-18 | 2004-03-17 | Angiotensin-converting enzyme inhibitory peptides |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009236034A Division AU2009236034B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
| AU2009236033A Division AU2009236033B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004222435A1 AU2004222435A1 (en) | 2004-09-30 |
| AU2004222435B2 true AU2004222435B2 (en) | 2009-12-17 |
Family
ID=33027809
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004222435A Ceased AU2004222435B2 (en) | 2003-03-18 | 2004-03-17 | Angiotensin-converting enzyme inhibitory peptides |
| AU2009236033A Ceased AU2009236033B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
| AU2009236034A Ceased AU2009236034B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009236033A Ceased AU2009236033B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
| AU2009236034A Ceased AU2009236034B2 (en) | 2003-03-18 | 2009-11-12 | Angiotensin-converting enzyme inhibitory peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7833985B2 (enExample) |
| EP (3) | EP1605969B1 (enExample) |
| JP (3) | JP4283848B2 (enExample) |
| KR (3) | KR101077801B1 (enExample) |
| CN (1) | CN100402089C (enExample) |
| AU (3) | AU2004222435B2 (enExample) |
| CA (3) | CA2743313C (enExample) |
| CY (1) | CY1114072T1 (enExample) |
| DK (1) | DK1605969T3 (enExample) |
| ES (3) | ES2400308T3 (enExample) |
| PL (3) | PL1938832T3 (enExample) |
| PT (1) | PT1605969E (enExample) |
| TW (3) | TWI411441B (enExample) |
| WO (1) | WO2004082709A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4046708B2 (ja) * | 2004-06-04 | 2008-02-13 | 明治製菓株式会社 | ３−アルケニルセフェム化合物の製造方法 |
| JP2006219420A (ja) * | 2005-02-10 | 2006-08-24 | Nagase Chemtex Corp | 抗高血圧剤 |
| US20090143311A1 (en) * | 2005-04-28 | 2009-06-04 | Luppo Edens | Compositions comprising tripeptides inhibiting ace |
| ZA200708791B (en) * | 2005-04-28 | 2009-08-26 | Unilever Plc | Peptides having an ace inhibiting effect |
| WO2006114192A1 (en) * | 2005-04-28 | 2006-11-02 | Unilever N.V. | Peptides having an ace inhibiting effect |
| ZA200708795B (en) * | 2005-04-28 | 2009-08-26 | Unilever Plc | Peptides having a healthy benefit and compositions comprising them |
| ATE453399T1 (de) * | 2005-05-24 | 2010-01-15 | Chr Hansen As | Isolierte dipeptide mit ace-inhibitionseffekt |
| JP4994093B2 (ja) * | 2006-04-13 | 2012-08-08 | ロート製薬株式会社 | 育毛剤 |
| CN100456948C (zh) * | 2006-06-30 | 2009-02-04 | 北京三友汇智生物技术有限公司 | 一种燕麦肽及其提取方法 |
| KR100787949B1 (ko) * | 2007-08-29 | 2007-12-24 | 한양대학교 산학협력단 | 대두 발효 조성물의 제조방법 및 이 조성물로부터 유래된펩타이드 |
| JP2009073765A (ja) * | 2007-09-20 | 2009-04-09 | Nitsukoku Seifun Kk | アンジオテンシン変換酵素（ａｃｅ）阻害剤組成物及びその製造方法 |
| JP2010163400A (ja) * | 2009-01-19 | 2010-07-29 | Kikkoman Corp | 新規アンジオテンシン変換酵素阻害ペプチド |
| CN101618207B (zh) * | 2009-06-17 | 2011-08-03 | 中国科学院大连化学物理研究所 | 多肽在制备ace抑制剂及降血压药物中的应用 |
| CN102665749B (zh) * | 2009-07-13 | 2014-09-17 | 不二制油株式会社 | 口服抗炎剂和口服抗炎肽 |
| CN101696233B (zh) * | 2009-10-29 | 2012-02-01 | 吉林大学 | 蛋清蛋白血管紧张素转化酶抑制肽及其制备 |
| JP5654290B2 (ja) * | 2010-08-27 | 2015-01-14 | ユニチカ株式会社 | アンジオテンシン変換酵素阻害ペプチド及びその製造方法。 |
| CN102399261B (zh) * | 2010-09-07 | 2014-06-25 | 任发政 | 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 |
| CN102475884B (zh) * | 2010-11-29 | 2013-08-14 | 中国科学院大连化学物理研究所 | 四个多肽在制备ace抑制剂及降血压药物中的应用 |
| CN102276690B (zh) * | 2011-08-05 | 2013-03-20 | 成都中医药大学 | 降血压功能性多肽及其用途 |
| JP6296722B2 (ja) * | 2012-07-31 | 2018-03-20 | サンスター株式会社 | 米糠酵素処理組成物 |
| KR101481416B1 (ko) * | 2012-10-17 | 2015-01-13 | 건국대학교 산학협력단 | 안지오텐신 전환 효소 저해 활성을 갖는 펩타이드 |
| JP2014141462A (ja) * | 2012-12-27 | 2014-08-07 | Raffinee International Co Ltd | ペプチド、並びに、アンジオテンシン変換酵素阻害剤、抗高血圧剤、及び飲食品 |
| US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
| CN108271917A (zh) | 2013-03-08 | 2018-07-13 | 艾斯姆食品公司 | 大米蛋白补充剂 |
| CN103172698B (zh) * | 2013-04-10 | 2015-02-18 | 华东理工大学 | 降血压多肽 |
| CN103242430B (zh) * | 2013-05-31 | 2014-10-08 | 南京中医药大学 | 血管紧张素转化酶抑制肽及其制备方法和应用 |
| CN103290086B (zh) * | 2013-06-25 | 2015-01-14 | 广州合诚实业有限公司 | 具有ace抑制活性的绿豆蛋白肽及其制备方法与应用 |
| CN104558110B (zh) * | 2013-10-21 | 2018-06-08 | 中国科学院大连化学物理研究所 | 具有ace抑制活性的多肽及其在降血压药物中的应用 |
| CN104558109B (zh) * | 2013-10-21 | 2018-06-08 | 中国科学院大连化学物理研究所 | 源于油菜花粉的具有ace抑制活性的多肽化合物及应用 |
| CN104447948B (zh) * | 2014-11-25 | 2017-12-08 | 肽能九号生物科技有限公司 | 一种从荠菜中分离获得的降血压多肽 |
| US10676505B2 (en) | 2016-06-16 | 2020-06-09 | Sunstar Inc. | Tripeptides having angiotensin converting enzyme inhibitory activity and uses thereof |
| CN110028549B (zh) * | 2016-07-07 | 2022-08-05 | 华东理工大学 | 降血压肽和降血压蛋白质及其应用 |
| CN110868870A (zh) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | 大米产物及制备它们的系统和方法 |
| WO2019006954A1 (zh) * | 2017-07-07 | 2019-01-10 | 广州世优生物科技有限公司 | 含硫二肽在制备降血压药物或保健品中的应用 |
| CN110498833B (zh) * | 2019-08-30 | 2021-01-15 | 华南理工大学 | 一种具有ace抑制作用的三肽及其应用 |
| CA3160647A1 (en) * | 2019-12-09 | 2021-06-17 | Societe Des Produits Nestle S.A. | Beverage paste |
| JP7391738B2 (ja) * | 2020-03-19 | 2023-12-05 | Ｋｉｓｃｏ株式会社 | ペプチド、及び苦味付与剤 |
| CN111548387B (zh) * | 2020-03-31 | 2020-12-18 | 华南农业大学 | 一种具有降血压功效的寡肽及其制备方法与应用 |
| CN111471086B (zh) * | 2020-04-16 | 2023-01-24 | 河南省农业科学院 | 芝麻多肽及其制备方法和应用 |
| CN111825754B (zh) * | 2020-07-16 | 2022-02-11 | 河南省农业科学院 | 一种从芝麻蛋白中获得的具有降血压与降血糖活性的多肽 |
| WO2022168413A1 (ja) * | 2021-02-04 | 2022-08-11 | ユーハ味覚糖株式会社 | デプレスタチン含有組成物の製造方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0445606A1 (en) * | 1990-02-27 | 1991-09-11 | The Agency of Industrial Science and Technology | Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides |
| EP1018341A1 (en) * | 1997-09-26 | 2000-07-12 | Calpis Co., Ltd. | Antistress agents and functional foods |
| EP1092724A2 (en) * | 1999-10-15 | 2001-04-18 | The Nippon Synthetic Chemical Industry Co., Ltd. | Angiotensin converting enzyme inhibitor |
| WO2001068115A1 (en) * | 2000-03-13 | 2001-09-20 | Monsanto Technology Llc | Process for producing peptide sequences possessing anti-hypertension activity |
| WO2001081368A2 (en) * | 2000-04-21 | 2001-11-01 | Monsanto Technology Llc | Blood-pressure reducing polypeptides containing vpp derived from microorganisms |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52148631A (en) | 1976-06-01 | 1977-12-10 | Kitazato Daigaku Yakurigakubu | Enzym obstruction agent |
| DE3112394A1 (de) * | 1980-07-22 | 1982-07-08 | Eltreva AG, 4147 Aesch | "einrichtung zur luftregulierung einer energiefassade" |
| JPS6023085B2 (ja) | 1981-12-23 | 1985-06-05 | 工業技術院長 | アンジオテンシン転換酵素阻害剤 |
| US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US5156840A (en) * | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| JPS6023086B2 (ja) | 1982-09-04 | 1985-06-05 | 工業技術院長 | アンジオテンシン転換酵素阻害剤 |
| JPS6023087A (ja) | 1983-07-20 | 1985-02-05 | Canon Inc | リボンカセツト |
| JPS6023086A (ja) | 1983-07-20 | 1985-02-05 | Canon Inc | リボンカセツト |
| DE3485587D1 (de) * | 1983-08-16 | 1992-04-23 | Univ Georgia Res Found | Herstellung von aminocyclopropancarbonsaeuren und von peptiden. |
| JPS6136226A (ja) | 1984-07-28 | 1986-02-20 | Agency Of Ind Science & Technol | アンジオテンシン転換酵素阻害剤 |
| JPS6136227A (ja) | 1984-07-28 | 1986-02-20 | Agency Of Ind Science & Technol | アンジオテンシン転換酵素阻害剤 |
| JPS6286741A (ja) | 1985-10-11 | 1987-04-21 | Mitsubishi Electric Corp | パタ−ンの位置合わせずれ量評価方法 |
| JP2805032B2 (ja) | 1988-07-27 | 1998-09-30 | 工業技術院長 | アンジオテンシン変換酵素阻害剤 |
| JP2873318B2 (ja) | 1989-03-14 | 1999-03-24 | 工業技術院長 | 血圧降下剤 |
| JPH0311097A (ja) | 1989-06-07 | 1991-01-18 | Senmi Ekisu Kk | 新規ペプチド |
| JPH0623086B2 (ja) | 1989-07-19 | 1994-03-30 | 花王株式会社 | 洗浄剤組成物 |
| JP3103363B2 (ja) * | 1990-03-30 | 2000-10-30 | 昭和産業株式会社 | 新規トリペプチド及び血圧降下剤 |
| JP3073762B2 (ja) | 1990-10-03 | 2000-08-07 | 日本合成化学工業株式会社 | アンギオテンシン変換酵素阻害剤含有組成物の製造方法 |
| JPH06136227A (ja) | 1992-10-22 | 1994-05-17 | Nippon Steel Chem Co Ltd | 熱可塑性樹脂組成物 |
| JP3357097B2 (ja) | 1992-10-27 | 2002-12-16 | 株式会社クラレ | 耐衝撃性メタクリル樹脂組成物 |
| JP2820868B2 (ja) | 1993-08-27 | 1998-11-05 | 日清食品株式会社 | アンジオテンシン変換酵素阻害蛋白分解物 |
| ES2170105T3 (es) * | 1993-10-04 | 2002-08-01 | Pasteur Institut | Compuestos que modifican la transmision serotoninergica; aplicaciones diagnosticas y terapeuticas. |
| US5558993A (en) * | 1994-06-17 | 1996-09-24 | The Regents Of The University Of California | Cloned Borrelia burgdorferi virulence protein |
| JP3135812B2 (ja) | 1995-03-01 | 2001-02-19 | 日清食品株式会社 | アンジオテンシン変換酵素阻害ペプチドおよびその製造方法 |
| JP3567012B2 (ja) | 1995-03-28 | 2004-09-15 | 雪印乳業株式会社 | 新規ペプチド及びその利用 |
| JP3028411B2 (ja) * | 1997-09-26 | 2000-04-04 | カルピス株式会社 | トリペプチド高生産性ラクトバチルス・ヘルベチカス乳酸菌 |
| CN1377276A (zh) * | 1999-08-09 | 2002-10-30 | 特里帕普股份公司 | 含有三肽的药用组合物 |
| FI113741B (fi) * | 1999-11-01 | 2004-06-15 | Valio Oy | Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi |
| WO2002062973A2 (en) * | 2001-02-07 | 2002-08-15 | Novozymes A/S | Lipase variants |
| JP4144696B2 (ja) | 2002-11-07 | 2008-09-03 | タイヨーエレック株式会社 | 遊技機 |
-
2004
- 2004-03-15 TW TW100111621A patent/TWI411441B/zh not_active IP Right Cessation
- 2004-03-15 TW TW097129374A patent/TWI344371B/zh not_active IP Right Cessation
- 2004-03-15 TW TW093106867A patent/TWI328457B/zh not_active IP Right Cessation
- 2004-03-17 WO PCT/JP2004/003588 patent/WO2004082709A1/en not_active Ceased
- 2004-03-17 JP JP2006507670A patent/JP4283848B2/ja not_active Expired - Lifetime
- 2004-03-17 CN CNB2004800112694A patent/CN100402089C/zh not_active Expired - Lifetime
- 2004-03-17 KR KR1020117000078A patent/KR101077801B1/ko not_active Expired - Fee Related
- 2004-03-17 CA CA2743313A patent/CA2743313C/en not_active Expired - Fee Related
- 2004-03-17 CA CA2526891A patent/CA2526891C/en not_active Expired - Fee Related
- 2004-03-17 US US10/549,176 patent/US7833985B2/en not_active Expired - Fee Related
- 2004-03-17 EP EP04721339A patent/EP1605969B1/en not_active Expired - Lifetime
- 2004-03-17 EP EP09172830A patent/EP2145630B1/en not_active Expired - Lifetime
- 2004-03-17 AU AU2004222435A patent/AU2004222435B2/en not_active Ceased
- 2004-03-17 PL PL08153738T patent/PL1938832T3/pl unknown
- 2004-03-17 PL PL09172830T patent/PL2145630T3/pl unknown
- 2004-03-17 ES ES08153738T patent/ES2400308T3/es not_active Expired - Lifetime
- 2004-03-17 CA CA2743539A patent/CA2743539C/en not_active Expired - Fee Related
- 2004-03-17 PL PL04721339T patent/PL1605969T3/pl unknown
- 2004-03-17 KR KR1020117000079A patent/KR101078628B1/ko not_active Expired - Fee Related
- 2004-03-17 PT PT47213392T patent/PT1605969E/pt unknown
- 2004-03-17 DK DK04721339.2T patent/DK1605969T3/da active
- 2004-03-17 KR KR1020057017447A patent/KR101119449B1/ko not_active Expired - Fee Related
- 2004-03-17 EP EP08153738A patent/EP1938832B1/en not_active Expired - Lifetime
- 2004-03-17 ES ES09172830T patent/ES2398788T3/es not_active Expired - Lifetime
- 2004-03-17 ES ES04721339T patent/ES2400561T3/es not_active Expired - Lifetime
-
2008
- 2008-12-01 JP JP2008306269A patent/JP4369986B2/ja not_active Expired - Lifetime
- 2008-12-01 JP JP2008306249A patent/JP4369985B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-12 US US12/483,676 patent/US7943578B2/en not_active Expired - Fee Related
- 2009-11-12 AU AU2009236033A patent/AU2009236033B2/en not_active Ceased
- 2009-11-12 AU AU2009236034A patent/AU2009236034B2/en not_active Ceased
-
2013
- 2013-04-26 CY CY20131100344T patent/CY1114072T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0445606A1 (en) * | 1990-02-27 | 1991-09-11 | The Agency of Industrial Science and Technology | Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides |
| EP1018341A1 (en) * | 1997-09-26 | 2000-07-12 | Calpis Co., Ltd. | Antistress agents and functional foods |
| EP1092724A2 (en) * | 1999-10-15 | 2001-04-18 | The Nippon Synthetic Chemical Industry Co., Ltd. | Angiotensin converting enzyme inhibitor |
| WO2001068115A1 (en) * | 2000-03-13 | 2001-09-20 | Monsanto Technology Llc | Process for producing peptide sequences possessing anti-hypertension activity |
| WO2001081368A2 (en) * | 2000-04-21 | 2001-11-01 | Monsanto Technology Llc | Blood-pressure reducing polypeptides containing vpp derived from microorganisms |
Non-Patent Citations (1)
| Title |
|---|
| Skeggs et al., Journal of Experimental Medicine, 1968, 128, 13-34 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004222435B2 (en) | Angiotensin-converting enzyme inhibitory peptides | |
| JP5417405B2 (ja) | アンジオテンシン変換酵素阻害性降圧ペプチド組成物の製造方法 | |
| WO2014002571A1 (ja) | アンジオテンシン変換酵素阻害ジペプチド | |
| HK1084604B (en) | Angiotensin-converting enzyme inhibitory peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: SUNTORY HOLDINGS LIMITED Free format text: FORMER APPLICANT(S): SUNTORY LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |